Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

HLA-C*12:02 is strongly associated with Xuesaitong-induced cutaneous adverse drug reactions

The Pharmacogenomics Journal volume 19, pages 277–285 (2019)Cite this article

Subjects

Abstract

Xuesaitong (XST) is mainly used to treat cardiovascular and cerebrovascular diseases, sometimes causing cutaneous adverse drug reactions (cADRs) with unknown mechanisms of pathogenicity or risk factors. We aimed to verify whether human leukocyte antigen (HLA) alleles are associated with XST-related cADRs in Han Chinese population. We carried out an association study including 12 subjects with XST-induced cADRs, 283 controls, and 28 XST-tolerant subjects. Five out of 12 patients with XST-induced cADRs carried HLA-C*12:02, and all of them received XST via intravenous drip. The carrier frequency of HLA-C*12:02 was significantly high compare to that of the control population (Pc = 4.4 × 10−4, odds ratio (OR) = 21.75, 95% CI = 5.78–81.88). Compared with that of the XST-tolerant group, the patients who received XST through intravenous drip presented a higher OR of cADRs (Pc = 0.011, OR = 27.00, 95% CI = 2.58–282.98). The results suggest that HLA-C*12:02 is a potentially predictive marker of XST-induced cADRs in Han Chinese, especially when XST is administered via intravenous drip.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Zhang X, Wu J, Zhang B. Xuesaitong injection as one adjuvant treatment of acute cerebral infarction: a systematic review and meta-analysis. BMC Complem Altern. 2015;15:36.

    Article  Google Scholar 

  2. Yao DL. Curative effect of Xuesaitong injection on acute cerebral infarction of 50 patients. Prac Clin Med. 2007;12:21–2.

  3. Yang PF, Song XY, Chen NH. Advances in pharmacological studies of Panax notoginseng saponins on brain ischemia-reperfusion injury. Acta Pharm Sin. 2016;51:1039–46.

    Google Scholar 

  4. He W, Xu XJ. Attenuation of brain inflammatory response after focal cerebral ischemia/reperfusion with Xuesaitong injection in rats. CHIN J INTEGR MED/1234. 2006;12:203–6.

    Article  CAS  Google Scholar 

  5. Wang L, Li Z, Zhao X, Liu W, Liu Y, Yang J, et al. A network study of chinese medicine xuesaitong injection to elucidate a complex mode of action with multicompound, multitarget, and multipathway. Evid-Based Complement Altern Med. 2013;2013:652373.

    Google Scholar 

  6. Liu J, Sun K, Zheng C, Chen X, Zhang W, Wang Z. et al. Pathway as a pharmacological target for herbal medicines: an investigation from reduning injection. PLoS ONE. 2015;10:e0123109

    Article  Google Scholar 

  7. Chen W. Analysis on 13 cases of adverse drug reaction by xuesaitong injection. J N Pharmacy 2013;5:16.

  8. Ma H. 1 cases of severe erythematous erythematous drug eruption caused by Xuesaitong injection. Derm Vener Dis. 2007;29:57–57.

    CAS  Google Scholar 

  9. Ju H, Ming P, Zhong W, Wu L. 2 cases of Xuesaitong induced acute generalized exanthematous pustulosis. J Clin Dep Dermatol. 2005;34:693–4.

    Google Scholar 

  10. Xiang Z, Qiao T, Xiao H, Kang T-G, Dou D, Li H, et al. The anaphylactoid constituents in Xue-Sai-Tong injection. Planta Med. 2013;79:1043–50.

    Article  CAS  Google Scholar 

  11. Xu Y, Dou D, Ran X, Liu C, Chen J. Integrative analysis of proteomics and metabolomics of anaphylactoid reaction induced by Xuesaitong injection. J Chromatogr. 2015;1416:103–11.

    Article  CAS  Google Scholar 

  12. Cao ZH, Wei ZY, Zhu QY, Zhang JY, Yang L, Qin SY, et al. HLA-B*58:01 allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese. Pharmacogenomics. 2012;13:1193–201.

    Article  CAS  Google Scholar 

  13. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358:568–79.

    Article  Google Scholar 

  14. Barbaud A, Waton J, Herbeth B, Bursztejn AC, Bollaert M, Schmutz JL, et al. Comparison of cytokine gene polymorphism in drug-induced maculopapular eruption, urticaria and drug reaction with eosinophilia and systemic symptoms (DRESS). J Eur Acad Dermatol Venereol. 2014;28:491–9.

    Article  CAS  Google Scholar 

  15. Ueta M, Sotozono C, Inatomi T, Kojima K, Hamuro J, Kinoshita S. Association of Fas Ligand gene polymorphism with Stevens-Johnson syndrome. Br J Ophthalmol. 2008;92:989–91.

    Article  CAS  Google Scholar 

  16. Bharadwaj M, Illing P, Theodossis A, Purcell AW, Rossjohn J, McCluskey J. Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex. Annu Rev Pharmacol Toxicol. 2012;52:401–31.

    Article  CAS  Google Scholar 

  17. Goncalo M, Coutinho I, Teixeira V, Gameiro AR, Brites MM, Nunes R, et al. HLA-B*58:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis in a Portuguese population. Br J Dermatol. 2013;169:660–5.

    Article  CAS  Google Scholar 

  18. Zhang Y, Wang J, Zhao LM, Peng W, Shen GQ, Xue L, et al. Strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients. Eur J Clin Pharmacol. 2011;67:885–7.

    Article  Google Scholar 

  19. Chen P, Lin JJ, Lu CS, Ong CT, Hsieh PF, Yang CC, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med. 2011;364:1126–33.

    Article  CAS  Google Scholar 

  20. Illing PT, Vivian JP, Purcell AW, Rossjohn J, McCluskey J. Human leukocyte antigen-associated drug hypersensitivity. Curr Opin Immunol. 2013;25:81–9.

    Article  CAS  Google Scholar 

  21. Son YM, Lee JR, Roh JY. Causality assessment of cutaneous adverse drug reactions. Ann Dermatol. 2011;23:432–8.

    Article  CAS  Google Scholar 

  22. Kitts A, Feolo M, Helmberg W. The major histocompatibility complex database, DBMHC. In: Jo Mc-Entyre, editor. The NCBI handbook - NCBI Bookshelf. Bethesda, MD: National Center for Biotechnology Information; 2003.

  23. Trachtenberg E, Vinson M, Hayes E, Hsu YM, Houtchens K, Erlich H, et al. HLA class I (A, B, C) and class II (DRB1, DQA1, DQB1, DPB1) alleles and haplotypes in the Han from southern China. Tissue Antigens. 2007;70:455–63.

    Article  CAS  Google Scholar 

  24. Yan S, Chen SA, Zhang W, Yang F, Yang Y, Zhu Q, et al. HLA-A*02 alleles are associated with tetanus antitoxin-induced exanthematous drug eruptions in Chinese patients. Pharm Genom. 2016;26:538–46.

    Article  CAS  Google Scholar 

  25. Rteam R, Team R, Development Core, Team R, Team R, Null RDCT. R: a language and environment for statistical computing. Computing. 2014;14:12–21.

    Google Scholar 

  26. Haldane JB. The estimation and significance of the logarithm of a ratio of frequencies. Ann Hum Genet. 1956;20:309–11.

    Article  CAS  Google Scholar 

  27. Yang F, Gu B, Zhang L, Xuan J, Luo H, Zhou P, et al. HLA-B*13:01 is associated with salazosulfapyridine-induced drug rash with eosinophilia and systemic symptoms in Chinese Han population. Pharmacogenomics. 2014;15:1461–9.

    Article  CAS  Google Scholar 

  28. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The protein data bank. Nucleic Acids Res. 2000;28:235–42.

    Article  CAS  Google Scholar 

  29. Kaur G, Gras S, Mobbs JI, Vivian JP, Cortes A, Barber T, et al. Structural and regulatory diversity shape HLA-C protein expression levels. NAT COMMUN/11329. 2017;8:15924.

    Article  CAS  Google Scholar 

  30. Schwede T, Kopp J, Guex N, Peitsch MC. SWISS-MODEL: An automated protein homology-modeling server. Nucleic Acids Res. 2003;31:3381–5.

    Article  CAS  Google Scholar 

  31. Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallogr D Biol Crystallogr. 2010;66:486–501.

    Article  CAS  Google Scholar 

  32. Delano WL. The PyMOL molecular graphics system. My Publ. 2002;30:442–54.

    Google Scholar 

  33. Unni S, Huang Y, Hanson RM, Tobias M, Krishnan S, Li WW, et al. Web servers and services for electrostatics calculations with APBS and PDB2PQR. J Comput Chem. 2011;32:1488–91.

    Article  CAS  Google Scholar 

  34. Pirmohamed M. Pharmacogenetics of idiosyncratic adverse drug reactions. Handb Exp Pharmacol. 2010;196:477–91.

  35. Posadas SJ, Pichler WJ. Delayed drug hypersensitivity reactions - new concepts. Clin Exp Allerg. 2007;37:989–99.

    Article  CAS  Google Scholar 

  36. Yang Y, Chen S, Yang F, Zhang L, Alterovitz G, Zhu H, et al. HLA-B*51:01 is strongly associated with clindamycin-related cutaneous adverse drug reactions. Pharmacogenomics J. 2016;17:501–5.

    Article  Google Scholar 

  37. Pistone G, Gurreri R, Alaimo R, Curiale S, Bongiorno MR. Gender differences in adverse drug reactions in dermatological patients in west Sicily: an epidemiological study. J Dermatol Treat. 2014;25:510–2.

    Article  Google Scholar 

  38. Nicolson TJ, Mellor HR, Roberts RR. Gender differences in drug toxicity. Trends Pharmacol Sci. 2010;31:108–14.

    Article  CAS  Google Scholar 

  39. Loll B, Fabian H, Huser H, Hee CS, Ziegler A, Uchanska-Ziegler B, et al. Increased conformational flexibility of HLA-B*27 subtypes associated with ankylosing spondylitis. Arthritis Rheumatol. 2016;68:1172–82.

    CAS  PubMed  Google Scholar 

  40. Mabuchi T, Ota T, Manabe Y, Ikoma N, Ozawa A, Terui T, et al. HLA-C*12:02 is a susceptibility factor in late-onset type of psoriasis in Japanese. J Dermatol. 2014;41:697–704.

    Article  CAS  Google Scholar 

  41. Liao H-T, Lin K-C, Chang Y-T, Chen C-H, Liang T-H, Chen W-S, et al. Human leukocyte antigen and clinical and demographic characteristics in psoriatic arthritis and psoriasis in Chinese patients. J Rheumatol. 2008;35:891–5.

    PubMed  Google Scholar 

  42. Yun J, Mattsson J, Schnyder K, Fontana S, Largiadèr CR, Pichler WJ, et al. Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response. Clin Exp Allergy. 2013;43:1246–55.

    Article  CAS  Google Scholar 

  43. Liu Y, Ma H, Zhang JW, Deng MC, Yang L. Influence of ginsenoside Rh1 and F1 on human cytochrome p450 enzymes. Planta Med. 2006;72:126–31.

    Article  CAS  Google Scholar 

  44. Han M, Fu S, Fang XL. [Comparison between the characteristics of absorption and pharmacokinetic behavior of ginsenoside Rg1 and ginsenoside Rb, of Panax notoginseng saponins]. Yao xue xue bao = Acta Pharm Sin. 2007;42:849.

    CAS  Google Scholar 

  45. Liu Y, Zhang JW, Li W, Ma H, Sun J, Deng MC, et al. Ginsenoside metabolites, rather than naturally occurring ginsenosides, lead to inhibition of human cytochrome P450 enzymes. Toxicol Sci. 2006;91:356–64.

    Article  CAS  Google Scholar 

  46. Zhang QY, Dunbar D, Ostrowska A, Zeisloft S, Yang J, Kaminsky LS. Characterization of human small intestinal cytochromes P-450. Drug Metab Dispos. 1999;27:804–9.

    CAS  PubMed  Google Scholar 

  47. Nelson MR, Bacanu SA, Mosteller M, Li L, Bowman CE, Roses AD, et al. Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions. Pharmacogenomics J. 2008;9:23–33.

    Article  Google Scholar 

Download references

Acknowledgements

This work was supported by the National Key Research and Development Program (2016YFC0905000, 2016 YFC0905001), the National Natural Science Foundation of China (grants 81472873, 81071287, 31371274, 81770725 and 81650004), Science and Technology Commission of Shanghai Municipality (14DJ1400100), Scientific and Technological Research in Open Collaborative Projects of Henan Province (152106000044) and HHS|NIH|U.S. National Library of Medicine (4R00LM009826-03). We thank the patients for their cooperation.

Author information

Author notes

  1. These authors contributed equally: Sijia Yan, Hao Xiong, Fengmin Shao.

Authors and Affiliations

  1. Children’s Hospital & Institutes of Biomedical Sciences, Fudan University, Shanghai, 200032, China

    Sijia Yan, Zheng Qi, Lin He, Menglin Jiang, Yu Su, Huizhong Zhu, Shengying Qin & Qinghe Xing

  2. Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, 200040, China

    Hao Xiong, Fanping Yang, Shengan Chen, Qinyuan Zhu & Xiaoqun Luo

  3. Department of Nephrology, Henan Provincial People’s Hospital (Zhengzhou University People’s Hospital), Zhengzhou, Henan, 450003, China

    Fengmin Shao

  4. Institutes of Biomedical Sciences, Fudan University, Shanghai, 200032, China

    Wen Zhang

  5. Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai, 200030, China

    Lin He & Shengying Qin

Authors
  1. Sijia Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hao Xiong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fengmin Shao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wen Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fanping Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zheng Qi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shengan Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Lin He
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Menglin Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yu Su
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Huizhong Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Shengying Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Qinyuan Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Xiaoqun Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Qinghe Xing
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Xiaoqun Luo or Qinghe Xing.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yan, S., Xiong, H., Shao, F. et al. HLA-C*12:02 is strongly associated with Xuesaitong-induced cutaneous adverse drug reactions. Pharmacogenomics J 19, 277–285 (2019). https://doi.org/10.1038/s41397-018-0051-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41397-018-0051-3

Search

Advanced search

Quick links